CANCER GENETICS, INC. (NASDAQ:CGIX) Files An 8-K Other Events
Item 8.01. Other Events
release announcing its receipt of approximately $950,000 with
respect to the New Jersey Technology Business Tax Certificate
Transfer (NOL) Program.
|
(d)
|
Exhibit No.
|
Description
|
|
|
99.1
|
Press Release, dated February 22, 2017
|
About CANCER GENETICS, INC. (NASDAQ:CGIX)
Cancer Genetics, Inc. is engaged in the field of personalized medicine, enabling precision medicine in the field of oncology through its diagnostic products and services, and molecular markers. The Company develops, commercializes and provides molecular- and biomarker-based tests and services that enable physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor and inform cancer treatment, and enable biopharmaceutical companies engaged in oncology trials to select candidate populations and manage adverse drug reactions by providing information regarding genomic factors influencing subject responses to therapeutics. It has a range of disease-focused oncology testing portfolio. Its molecular- and biomarker-based diagnostic services are provided for three sectors: cancer centers and hospitals, biotechnology and biopharmaceutical companies, and the research community. CANCER GENETICS, INC. (NASDAQ:CGIX) Recent Trading Information
CANCER GENETICS, INC. (NASDAQ:CGIX) closed its last trading session 00.00 at 2.55 with 438,429 shares trading hands.